GE HealthCare (GEHC) Q3 2026 Earnings
Includes $0.02 per share tariff refunds (IEEPA), $0.08 per share Spin-Off and other tax adjustments benefit, $0.03 per share acquisition-related charges, and $0.04 per share restructuring costs
How Did GEHC Stock React to Q3 2026 Earnings?
Did GEHC Beat Earnings? Q3 2026 Results
Yes. GE HealthCare reported Q3 2026 earnings of $1.34 a share on Oct 28, 2026, beating the $1.20 consensus estimate by 11.3%. Revenue was $5.5B against a $5.4B estimate.
GE HealthCare Technologies delivered a standout third quarter of 2026, posting adjusted EPS of $1.34 against a consensus estimate of $1.20, a beat of 11.29%, while revenue of $5.51 billion topped expectations by 3.01% and grew 7.2% year over year. The headline driver was broad operational momentum: adjusted EBIT margin expanded 180 basis points to 16.6%, fueled by volume leverage, pricing discipline, and productivity gains through the company's Heartbeat program, with Pharmaceutical Diagnostics surging 13.0% to $846.00 million and Patient Care Solutions, a segment that had drawn investor scrutiny ahead of the print, improving its segment EBIT margin by 480 basis points to 8.6%. Free cash flow nearly doubled to $793.00 million. Management responded to the strong quarter by lifting full-year 2026 guidance, now targeting adjusted EPS of $4.95 to $5.05 and organic revenue growth of approximately 4.0%, reflecting confidence that demand trends, anchored by a $23.70 billion backlog and healthy 4.0% organic order growth, remain durable heading into year-end.
- Volume leverage, pricing, and cost productivity drove Adjusted EBIT margin expansion of 180 bps to 16.6%
- Favorable year-over-year net tariff impact partially offset by inflation
- Organic orders growth of 4.0% and book-to-bill of 1.03x with backlog of $23.7 billion
- Pharmaceutical Diagnostics organic revenue grew 13.8%, the strongest segment organically
- Patient Care Solutions segment EBIT margin improved 480 bps year-over-year to 8.6%
- Heartbeat operational improvement program enabling disciplined cost management
“We delivered strong top-line growth and margin expansion across all segments, and robust EPS growth in the third quarter. This reflects our teams' commercial execution, disciplined operational focus enabled by Heartbeat, and continued customer adoption of our innovations. With our improved performance year-to-date and momentum in the business, we are raising guidance for the year.”
GE HealthCare CEO, on the earnings call
What Is GE HealthCare's Outlook?
GE HealthCare raised its full-year 2026 guidance: Organic revenue growth of ~4.0% (prior: 3.0%-4.0%); Adjusted EBIT margin of 15.5%-15.7% representing 20-40 bps expansion (prior: 15.4%-15.7%, 10-40 bps); Adjusted ETR of 20.0%-21.0% (reaffirmed); Adjusted EPS of $4.95-$5.05 representing 7.9%-10.1% growth (prior: $4.80-$5.00, 4.6%-9.0% growth); Free cash flow of $1.6B+ (prior: ~$1.6B). The 2025 baseline was: Organic revenue growth of 3.5%, Adjusted EBIT margin of 15.3%, Adjusted ETR of 20.2%, Adjusted EPS of $4.59, and Free cash flow of $1.5B.
GEHC YoY Financials
| Metric | Q3 2026 | Q3 2025 | Year over year |
|---|---|---|---|
| Revenue | $5.5B | $5.1B | +7.2% |
| Gross Profit | $2.2B | $2.0B | +11.8% |
| Operating Income | $805.0M | $653.0M | +23.3% |
| Net Income | $615.0M | $446.0M | +37.9% |
GEHC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.